Jamie Freedman
Executive Vice-President,
management team
Astra Zeneca
Sweden
Biography
Jamie was appointed Executive Vice-President, Oncology in April 2017. He is responsible for the global commercial performance of AstraZeneca’s marketed Oncology medicines, both mature and growth brands, and forthcoming launches from the Oncology portfolio. In addition, he plays a leadership role in setting the Oncology strategy for the organisation. Jamie joined MedImmune in 2012 playing a leading role in advancing MedImmune’s portfolio of projects across all therapeutic areas and, in particular, the broad portfolio of immuno-oncology projects including durvalumab and tremelimumab. Most of these projects are in pivotal trials and some are at various stages of registration for market approval. Jamie has degrees in biochemistry and medicine and is triple board certified in Internal Medicine and Haematology-Oncology with degrees from the University of California, San Francisco and Harvard, respectively. Prior to joining MedImmune, he held leadership roles in Oncology at GSK and Merck & Co where he oversaw portfolios of small molecules and biologics.
Research Interest
biologistics
